Giachelli, C. M. Mechanisms of vascular calcification in uremia 2004. Semin Nephrol 24: 401–402.

Leopold, J. A. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification 2015. Trends Cardiovasc Med 25: 267–274.

Shanahan, C. M., M. H. Crouthamel, A. Kapustin, and C. M. Giachelli. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate 2011. Circ Res 109: 697–711.

Liu, W., Y. Zhang, C. M. Yu, Q. W. Ji, M. Cai, and Y. X. Zhao. Zhou YJ Current understanding of coronary artery calcification 2015. J Geriatr Cardiol 12: 668–675.

Bostrom, K. I. Where do we stand on vascular calcification? 2016. Vascul Pharmacol 84: 8–14.

Zhang, L., J. Yao, Y. Yao, and K. I. Bostrom. Contributions of the Endothelium to Vascular Calcification 2021. Front Cell Dev Biol 9: 620882.

Mizobuchi, M., D. Towler, and E. Slatopolsky. Vascular calcification: the killer of patients with chronic kidney disease 2009. J Am Soc Nephrol 20: 1453–1464.

Niskanen, L., O. Siitonen, and M. Suhonen. Uusitupa MI Medial artery calcification predicts cardiovascular mortality in patients with NIDDM 1994. Diabetes Care 17: 1252–1256.

Rennenberg, R. J., A. G. Kessels, L. J. Schurgers, J. M. van Engelshoven, and P. W. de Leeuw. Kroon AA Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis 2009. Vasc Health Risk Manag 5: 185–197.

Deuell, K. A., A. Callegari, C. M. Giachelli, and M. E. Rosenfeld. Scatena M RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-alpha 2012. J Vasc Res 49: 510–521.

Masuda, M., S. Miyazaki-Anzai, M. Levi, T. C. Ting, and M. Miyazaki. PERK-eIF2alpha-ATF4-CHOP signaling contributes to TNFalpha-induced vascular calcification 2013. J Am Heart Assoc 2: e000238.

Wen, C., X. Yang, Z. Yan, M. Zhao, X. Yue, X. Cheng, Z. Zheng, K. Guan, J. Dou, and T. Xu. 2013. Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification. International Journal of Cardiology 168: 2242–2247.

Google Scholar 

Janeway, C. A. Jr. Approaching the asymptote? Evolution and revolution in immunology 1989. Cold Spring Harb Symp Quant Biol 54 Pt 1: 1–13.

Kim, H. J., H. Kim, J. H. Lee, and C. Hwangbo. Toll-like receptor 4 (TLR4): new insight immune and aging 2023. Immun Ageing 20: 67.

Kawai, T., and S. Akira. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors 2010. Nat Immunol 11: 373–384.

O’Neill, L. A., D. Golenbock, and A. G. Bowie. The history of Toll-like receptors - redefining innate immunity 2013. Nat Rev Immunol 13: 453–460.

Bolourani, S., M. Brenner, and P. Wang. The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis 2021. J Mol Med (Berl) 99: 1373–1384.

Song, Y., M. Hou, Z. Li, C. Luo, J. S. Ou, H. Yu, J. Yan, and L. Lu. TLR4/NF-kappaB/Ceramide signaling contributes to Ox-LDL-induced calcification of human vascular smooth muscle cells 2017. Eur J Pharmacol 794: 45–51.

Karbaschian, Z., M.J. Hosseinzadeh-Attar, L. Giahi, A. Golpaie, F. Masoudkabir, M. Talebpour, F. Kosari, N. Karbaschian, M. Hoseini, and M. Mazaherioun. 2013. Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery. Endocrine 44: 114–118.

Google Scholar 

Garten, A., S. Schuster, M. Penke, T. Gorski, T. de Giorgis, and W. Kiess. 2015. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nature Reviews Endocrinology 11: 535–546.

Google Scholar 

Dakroub, A., A. N. S, N. Younis, H. Bhagani, Y. Al-Dhaheri, G. Pintus, A. A. Eid, A. F. El-Yazbi, and A. H. Eid. Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders 2020. Cells 9.

Kim, S.R., Y.H. Bae, S.K. Bae, K.S. Choi, K.H. Yoon, T.H. Koo, H.O. Jang, I. Yun, K.W. Kim, and Y.G. Kwon. 2008. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochimica Et Biophysica Acta 1783: 886–895.

Google Scholar 

Lee, W.J., C.S. Wu, H. Lin, I.T. Lee, C.M. Wu, J.J. Tseng, M.M. Chou, and W.H. Sheu. 2009. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. International Journal of Obesity (London, England) 33: 465–472.

Google Scholar 

Mohammadi, M., F. Mianabadi, and H. Mehrad-Majd. 2019. Circulating visfatin levels and cancers risk: A systematic review and meta-analysis. Journal of Cellular Physiology 234: 5011–5022.

Google Scholar 

Chen, M.P., F.M. Chung, D.M. Chang, J.C. Tsai, H.F. Huang, S.J. Shin, and Y.J. Lee. 2006. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 91: 295–299.

Google Scholar 

Polyakova, Y.V., B.V. Zavodovsky, L.E. Sivordova, Y.R. Akhverdyan, and I.A. Zborovskaya. 2020. Visfatin and Rheumatoid Arthritis: Pathogenetic implications and clinical utility. Current Rheumatology Reviews 16: 224–239.

Google Scholar 

Camp, S.M., E. Ceco, C.L. Evenoski, S.M. Danilov, T. Zhou, E.T. Chiang, L. Moreno-Vinasco, B. Mapes, J. Zhao, and G. Gursoy. 2015. Unique Toll-like receptor 4 activation by NAMPT/PBEF induces NFkappaB signaling and inflammatory lung injury. Scientific Reports 5: 13135.

Google Scholar 

Revollo, J. R., A. Korner, K. F. Mills, A. Satoh, T. Wang, A. Garten, B. Dasgupta, Y. Sasaki, C. Wolberger, and R. R. Townsend et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme 2007. Cell Metab 6: 363–375.

Yoon, M.J., M. Yoshida, S. Johnson, A. Takikawa, I. Usui, K. Tobe, T. Nakagawa, J. Yoshino, and S. Imai. 2015. SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD + and function in mice. Cell Metabolism 21: 706–717.

Google Scholar 

Shaheer, A., A. Kumar, P. Menon, M. Jallo, and S. Basha. 2021. Effect of add-on therapy of sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on adipokines in type 2 diabetes mellitus. Journal of Clinical Medicine Research 13: 355–362.

Google Scholar 

Vallon, V., and S. Verma. 2021. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annual Review of Physiology 83: 503–528.

Google Scholar 

Monteiro, P., R.M. Bergenstal, E. Toural, S.E. Inzucchi, B. Zinman, S. Hantel, S.G. Kis, S. Kaspers, J.T. George, and D. Fitchett. 2019. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age and Ageing 48: 859–866.

Google Scholar 

Zinman, B., C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, et al. 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 373: 2117–2128.

Google Scholar 

Fitchett, D., S.E. Inzucchi, C.P. Cannon, D.K. McGuire, B.M. Scirica, O.E. Johansen, S. Sambevski, S. Kaspers, E. Pfarr, J.T. George, et al. 2019. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139: 1384–1395.

Google Scholar 

Raff, G. L., A. Abidov, S. Achenbach, D. S. Berman, L. M. Boxt, M. J. Budoff, V. Cheng, T. DeFrance, J. C. Hellinger, and R. P. Karlsberg et al. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography 2009. J Cardiovasc Comput Tomogr 3: 122–136.

Gupte, M., P. Umbarkar, and H. Lal. 2017. Mechanistic insights of empagliflozin-mediated cardiac benefits: Nearing the starting line : Editorial to: “Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes” by N. Hammoudi et al. Cardiovascular Drugs and Therapy 31: 229–232.

Google Scholar 

Vasamsetti, S. B., N. Natarajan, S. Sadaf, J. Florentin, and P. Dutta. Regulation of cardiovascular health and disease by visceral adipose tissue-derived metabolic hormones 2023. J Physiol 601: 2099–2120.

Kolb, H. Obese visceral fat tissue inflammation: from protective to detrimental? 2022. BMC Med 20: 494.

Gao, F., F. Si, S. Feng, Q. Yi, and R. Liu. 2016. Resistin Enhances Inflammatory Cytokine Production in Coronary Artery Tissues by Activating the NF-kappaB Signaling 2016. Biomed Res Int : 3296437.

Luo, X. H., L. L. Zhao, L. Q. Yuan, M. Wang, and H. Xie. Liao EY Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification 2009. J Bone Miner Res 24: 1461–1468.

Zhou, L., J. Y. Li, P. P. He, X. H. Yu, C. K. Tang, and Resistin. Potential biomarker and therapeutic target in atherosclerosis 2021. Clin Chim Acta 512: 84–91.

Hao, Q.Y., J. Yan, J.T. Wei, Y.H. Zeng, L.Y. Feng, D.D. Que, S.C. Li, J.B. Guo, Y. Fan, and Y.F. Ding. 2024. Prevotella copri promotes vascular calcification via lipopolysaccharide through activation of NF-κB signaling pathway. Gut Microbes 16: 2351532.

Google Scholar 

Wang, Z., Z. Wang, J. Zhu, X. Long, and J. Yan. Vitamin K2 can suppress the expression of Toll-like receptor 2 (TLR2) and TLR4, and inhibit calcification of aortic intima in ApoE(-/-) mice as well as smooth muscle cells 2018. Vascular 26: 18–26.

Zhang, F., J. Li, C. Gu, and H. Zhang. MiR-140-5p upregulation suppressed beta-glycerophosphate-induced vascular smooth muscle cell calcification via targeting TLR4 2022. Immunopharmacol Immunotoxicol 44: 295–305.

Disthabanchong, S., and P. Srisuwarn. Mechanisms of Vascular Calcification in Kidney Disease 2019. Adv Chronic Kidney Dis 26: 417–426.

Wu, X.T., Z. Yang, A.R. Ansari, K. Xiao, X.X. Pang, Y. Luo, and H. Song. 2018. Visfatin regulates the production of lipopolysaccharide-induced inflammatory cytokines through p38 signaling in murine macrophages. Microbial Pathogenesis 117: 55–59.

Google Scholar 

Abdalla, M.M.I. 2022. Role of visfatin in obesity-induced insulin resistance. World Journal of Clinical Cases 10: 10840–10851.

Google Scholar 

Kempf, C. L., J. H. Song, S. Sammani, T. Bermudez, V. Reyes Hernon, L. Tang, H. Cai, S. M. Camp, C. A. Johnson, and M. S. Basiouny et al. TLR4 Ligation by eNAMPT, a Novel DAMP, is Essential to Sulfur Mustard- Induced Inflammatory Lung Injury and Fibrosis 2024. Eur J Respir Med 6: 389–397.

Ok, C.Y., S. Park, H.O. Jang, M.K. Bae, and S.K. Bae. 2023. Involvement of the visfatin/toll-like receptor 4 signaling axis in human dental pulp cell senescence: Protection via toll-like receptor 4 blockade. Journal of Dental Sciences 18: 1177–1188.

Google Scholar 

Romacho, T., I. Valencia, M. Ramos-Gonzalez, S. Vallejo, M. Lopez-Esteban, O. Lorenzo, P. Cannata, A. Romero, A. San Hipolito-Luengo, J.F. Gomez-Cerezo, et al. 2020. Visfatin/eNampt induces endothelial dysfunction in vivo: A role for Toll-Like Receptor 4 and NLRP3 inflammasome. Scientific Reports 10: 5386.

Google Scholar 

Sun, B.L., X. Sun, C.L. Kempf, J.H. Song, N.G. Casanova, S.M. Camp, V. Reyes Hernon, M. Fallon, C. Bime, D.R. Martin, et al. 2023. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis. FASEB Journal 37: e22825.

Google Scholar 

Retnakaran, R., B.S. Youn, Y. Liu, A.J. Hanley, N.S. Lee, J.W. Park, E.S. Song, V. Vu, W. Kim, R. Tungtrongchitr, et al. 2008. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study. Clinical Endocrinology (Oxford) 69: 885–893.

Google Scholar 

Sandeep, S., K. Velmurugan, R. Deepa, and V. Mohan. 2007. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56: 565–570.

Google Scholar 

Madonna, R., S. Moscato, M.C. Cufaro, D. Pieragostino, L. Mattii, P. Del Boccio, S. Ghelardoni, R. Zucchi, and R. De Caterina. 2023. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3beta signalling pathway in diabetic cardiomyopathy. Cardiovascular Research 119: 1175–1189.

Google Scholar 

Zhou, H., S. Wang, P. Zhu, S. Hu, Y. Chen, and J. Ren. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission 2018. Redox Biol 15: 335–346.

Cai, W., K. Chong, Y. Huang, C. Huang, and L. Yin. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress 2024. Redox Biol 69: 103010.

Kolijn, D., S. Pabel, Y. Tian, M. Lodi, M. Herwig, A. Carrizzo, S. Zhazykbayeva, A. Kovacs, G.A. Fulop, and I. Falcao-Pires. 2021. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovascular Research 117: 495–507.

Google Scholar 

Li, C., J. Zhang, M. Xue, X. Li, F. Han, X. Liu, L. Xu, Y. Lu, Y. Cheng, and T. Li. 2019. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovascular Diabetology 18: 15.

Google Scholar 

Lu, C. W., C. J. Lee, Y. J. Hsieh, and B. G. Hsu. Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation 2023. Int J Mol Sci 24.